AIDSVAX

Last updated

AIDSVAX is an experimental HIV vaccine that was developed originally at Genentech in San Francisco, California, and later tested by the VaxGen company, a Genentech offshoot. [1] The development and trials of the vaccine received significant coverage in the international media, but American trials proved inconclusive. The vaccine was then tested on a group of at-risk individuals in Thailand.

In 1991, AIDSVAX originally consisted of the B envelope of recombinant gp120, a glycoprotein unique to HIV's surface, from a strain of the virus, MN, known at the time to infect people in the United States and Europe. The vaccine was designed to provoke the production of antibodies in subjects that would strip the gp120 protein off of the HIV viral particles, effectively disabling the virus so that it could not bind to or invade susceptible cells. Then, another group, infected with a second strain of HIV, A244, was discovered in 1995, and a revised, bivalent version of the vaccine was produced that combined elements of both MN and A244. Phase I and Phase II tests of the first version were promising, showing excellent safety in chimpanzees and humans and provoking production of HIV MN and A244 antibodies in 99% of human volunteers. [2]

VaxGen's leadership enthusiastically applied to the U.S. Food and Drug Administration (FDA) for permission to undertake Phase III studies in the U. S. on large numbers of at-risk volunteers. But since some of the Phase I and Phase II volunteers had become infected with HIV while taking the vaccine, showing that the vaccine was not 100% effective, and it was not proven that the vaccine itself hadn't caused these infections, the FDA and other members of the medical community hesitated and finally declined to approve Phase III testing "until more was learned about HIV immunity", despite the fact that early versions of successful vaccines have rarely been 100% effective, and even the 1955 Salk polio vaccine was only 70% effective, superseded as it was seven years later by the Sabin vaccine. With human lives at stake, however, the FDA could not risk condoning further trials until it knew what had caused the infections. [2]

Another problem with AIDSVAX was that it provoked an entirely humoral, antibody immune response in its subjects, unlike other HIV vaccines in development in Europe and elsewhere that were provoking balanced antibody and cellular defenses. [2]

In response, VaxGen turned to the international community, seeking a place that would sanction clinical trials of AIDSVAX, and after negotiating with AIDS-plagued officials in Africa and Asia, landed upon Thailand. Initial Phase II trials of AIDSVAX B/B alone in the US and AIDVAX B/E alone in Thailand were unsuccessful, with both vaccines failing to either prevent or weaken HIV infection, [3] so instead VaxGen began Thai trials of AIDSVAX B/E in combination with the Aventis-Pasteur vaccine, ALVAC-HIV, that uses genetic elements of several different HIV strains encapsulated in a canarypox virus vector. AIDSVAX B/E, moreover, contained elements of the HIV strain peculiar to Thailand's victims, E, as well as one common in the US, B. [2]

A report published in the December 2009 New England Journal of Medicine on this Thailand clinical trial, also known as the RV144 trial, of the vaccine known as "ALVAC-AIDSVAX B/E" showed the combination treatment's efficacy ranging from 26.1 to 31.4%, which though far from optimal makes the combination AIDSVAX-Aventis vaccine one of the first important milestones in the world's struggle to produce a globally effective HIV vaccine. However, during the study seven participants were removed from the study when the results showed they had already been found with an HIV-1 infection at baseline, which changed the result from 26.1 to 31.4% vaccination efficacy. [4]

Related Research Articles

HIV vaccine development In-progress vaccinations that may prevent or treat HIV infections

An HIV vaccine could be either a preventive vaccine or a therapeutic vaccine, which means it will either protect individuals from being infected with HIV or treat HIV-infected individuals. It could either induce an immune response against HIV or consist of preformed antibodies against HIV.

This is a list of AIDS-related topics, many of which were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition.

Original antigenic sin

Original antigenic sin, also known as antigenic imprinting or the Hoskins effect, refers to the propensity of the body's immune system to preferentially utilize immunological memory based on a previous infection when a second slightly different version of that foreign pathogen is encountered. This leaves the immune system "trapped" by the first response it has made to each antigen, and unable to mount potentially more effective responses during subsequent infections. Antibodies or T-cells induced during infections with the first variant of the pathogen are subject to a form of original antigenic sin, termed repertoire freeze.

Sanofi Pasteur the vaccines division of Sanofi

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.

Entry inhibitors, also known as fusion inhibitors, are a class of antiviral drugs that prevent a virus from entering a cell, for example, by blocking a receptor. Entry inhibitors are used to treat conditions such as HIV and hepatitis D.

GeoVax is a clinical-stage biotechnology company initially established primarily to develop an effective and safe vaccine against many serious human diseases for which there are significant unmet medical needs. GeoVax’ novel development platform builds on the proven clinical and commercial success of the Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax technology approach uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated. In human clinical trials of the company’s HIV vaccines, GeoVax demonstrated that VLPs are safe and eliciting both strong and durable humoral and cellular immune response.

A neutralizing antibody (NAb) is an antibody that defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically. Neutralization renders the particle no longer infectious or pathogenic. Neutralizing antibodies are part of the humoral response of the adaptive immune system against viruses, intracellular bacteria and microbial toxin. By binding specifically to surface structures (antigen) on an infectious particle, neutralizing antibodies prevent the particle from interacting with its host cells it might infect and destroy. Immunity due to neutralizing antibodies is also known as sterilizing immunity, as the immune system eliminates the infectious particle before any infection takes place.

RV 144, or the Thai trial, is the name of an HIV vaccine clinical trial combining two vaccines that failed on their own, vaccinating in Thailand over the course of 24 weeks in October 2003 then testing for HIV until July 2006, publicly releasing efficacy findings in September 2009. The initial report shows that the rate of HIV infection among volunteers who received the experimental vaccine was 31% lower than the rate of HIV infection in volunteers who received the placebo. However, the reduction was not great enough for the Ministry of Public Health in Thailand to support approving the vaccine; it was reported in 2019 that it would have licensed it if the reduction had been 50% or more.

The United States Military HIV Research Program was initiated by the United States Congress in 1986, in reaction to the threat of lost effectiveness of U.S./Allied troops due to HIV infection. The mission of MHRP is to develop an HIV-1 vaccine, provide prevention, care, and treatment, and conduct meaningful HIV/AIDS research for the global community through the President's Emergency Plan for AIDS Relief (PEPFAR). It is centered at the Walter Reed Army Institute of Research (WRAIR), and has established five international research sites in Africa and Asia. MHRP also partners with the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Thailand. MHRP works closely with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), most notably in the development of the RV144 HIV vaccine in Thailand. MHRP is the largest research program supported by the HJF.

Enzo Paoletti was an Italian-American virologist who developed the technology to express foreign antigens in vaccinia and other poxviruses. This advance led to the development of vaccines against multiple disease-causing pathogens.

HVTN 505 is a clinical trial testing an HIV vaccine regimen on research participants. The trial is conducted by the HIV Vaccine Trials Network and sponsored by the National Institute of Allergy and Infectious Diseases. Vaccinations were stopped in April 2013 due to initial results showing that the vaccine was ineffective in preventing HIV infections and lowering viral load among those participants who had become infected with HIV. All study participants will continue to be monitored for safety and any long-term effects.

MVA-B, or Modified Vaccinia Ankara B, is a particular HIV vaccine created to give immune resistance to infection by the human immunodeficiency virus. It was developed by a team of Spanish researchers at the Spanish National Research Council's Biotechnology National Centre headed by Dr. Mariano Esteban. The vaccine is based on the Modified vaccinia Ankara (MVA) virus used during the 1970s to help eradicate the smallpox virus. The B in the name "refers to HIV-B, the most common HIV subtype in Europe". It has been stated by Dr. Esteban that, in the future, the vaccine could potentially reduce the virulence of HIV to a "minor chronic infection akin to herpes".

SAV001-H is the first preventive HIV vaccine using a killed or "dead version" of HIV-1 virus.

Herpes simplex research includes all medical research that attempts to prevent, treat, or cure herpes, as well as fundamental research about the nature of herpes. Examples of particular herpes research include drug development, vaccines and genome editing. HSV-1 and HSV-2 are commonly thought of as oral and genital herpes respectively, but other members in the herpes family include chickenpox (varicella/zoster), cytomegalovirus, and Epstein-Barr virus. There are many more virus members that infect animals other than humans, some of which cause disease in companion animals or have economic impacts in the agriculture industry.

HIV/AIDS research Field of immunology research

HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.

Broadly Neutralizing HIV-1 Antibodies (bNAbs) are neutralizing antibodies which neutralize multiple HIV-1 viral strains. bNAbs are unique in that they target conserved epitopes of the virus, meaning the virus may mutate, but the targeted epitopes will still exist. In contrast, non-bNAbs are specific for individual viral strains with unique epitopes. The discovery of bNAbs has led to an important area of research, namely, discovery of a vaccine, not only limited to HIV, but also other rapidly mutating viruses like Influenza.

Anna-Lise WilliamsonMASSAf is a Professor of Virology at the University of Cape Town. Williamson obtained her PhD from the University of the Witwatersrand in 1985. Her area of expertise is human papillomavirus, but is also known on an international level for her work in developing vaccines for HIV. These vaccines have been introduce in phase 1 of clinical trial. Williamson has published more than 120 papers.

Susan Zolla-Pazner American research scientist

Susan Zolla-Pazner is an American research scientist who is a Professor of Medicine in the Division of Infectious Diseases and the Department of Microbiology at Mount Sinai School of Medicine and a guest investigator in the Laboratory of Molecular Immunology at The Rockefeller University, both in New York City. Zolla-Pazner's work has focused on how the immune system responds to the human immunodeficiency virus (HIV) and, in particular, how antibodies against the viral envelope develop in the course of infection.

Intrastructural help (ISH) is where T and B cells cooperate to help or suppress an immune response gene. ISH has proven effective for the treatment of influenza, rabies related lyssavirus, hepatitis B, and the HIV virus. This process was used in 1979 to observe that T cells specific to the influenza virus could promote the stimulation of hemagglutinin specific B cells and elicit an effective humoral immune response. It was later applied to the lyssavirus and was shown to protect raccoons from lethal challenge. The ISH principle is especially beneficial because relatively invariable structural antigens can be used for the priming of T-cells to induce humoral immune response against variable surface antigens. Thus, the approach has also transferred well for the treatment of hepatitis B and HIV.

The Immune Response Corporation (IRC) pioneered immunotherapeutic products. The firm was founded by Jonas Salk and Kevin Kimberlin when Kimberlin, "asked Salk to become lead scientific advisor for a new biotech company specializing in 'anti-idiotypes,' a novel vaccine technology," Salk called the proposal "liberating."

References

  1. ↑ Adis International, Ltd (2003). "HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen". Drugs in R&D. 4 (4): 249–53. doi:10.2165/00126839-200304040-00007. PMID   12848591.
  2. 1 2 3 4 Eaton ML. "VaxGen Fighting the AIDS Epidemic." Ethics and the Business of Bioscience. Stanford: Stanford University Press, 2004.
  3. ↑ McCarthy, Michael (November 2003). "AIDS vaccine fails in Thai trial". The Lancet. 362 (9397): 1728. doi:10.1016/S0140-6736(03)14886-6. PMID   14655660.
  4. ↑ Rerks-Ngarm, S; Pitisuttithum, P; Nitayaphan, S; Kaewkungwal, J; Chiu, J; Paris, R; Premsri, N; Namwat, C; de Souza, M; Adams, E; Benenson, M; Gurunathan, S; Tartaglia, J; McNeil, JG; Francis, DP; Stablein, D; Birx, DL; Chunsuttiwat, S; Khamboonruang, C; Thongcharoen, P; Robb, ML; Michael, NL; Kunasol, P; Kim, JH; MOPH-TAVEG, Investigators. (3 December 2009). "Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand". The New England Journal of Medicine. 361 (23): 2209–20. doi:10.1056/NEJMoa0908492. PMID   19843557.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.